Patent Licensing

How it works

A patent gives its owner the right to exclude others from making, using or selling the claimed invention — it is not itself a right to practise the invention, since other patents or regulations may still block that. Licensing takes that negative right and converts it into cash: the owner sells a covenant not to sue, paired with permission to operate within limits set by the agreement.

Every licence is scoped along four axes: exclusivity (exclusive, sole, or non-exclusive), field of use, territory, and term. Each narrower slice of scope can, in principle, be sold separately to a different party, so one patent can support several simultaneous licences if the fields or territories do not overlap.

Commercial terms typically stack an up-front fee, a running royalty on net sales of the licensed product, milestone payments tied to development or regulatory events, and a minimum annual royalty that keeps an exclusive licensee from sitting on unused rights. What counts as net sales, and whether the royalty applies to a component or to the whole end product, is a heavily negotiated and heavily litigated definition — it has to be written down precisely. Sublicensing rights and the owner's share of any sublicence income are separate negotiated terms, and audit rights, quarterly royalty reports, late-payment interest, and most-favoured-licensee clauses form the standard administrative apparatus around the deal.

US utility patents run twenty years from the earliest non-provisional filing date, adjusted for patent-office delay, and maintenance fees fall due on a statutory schedule after grant — missing one lapses the patent. University technology transfer offices license federally funded inventions under the Bayh-Dole framework and share proceeds with named inventors by written policy. Standard-essential patents carry fair, reasonable and non-discriminatory licensing commitments that cap pricing power in exchange for industry-wide adoption, and patent exhaustion means an authorised first sale extinguishes further royalty claims on that item, so where in the supply chain a licence is granted determines how much can ultimately be collected.

What it pays

Payment is quoted as a running royalty percentage of net sales, a fixed amount per unit, or a lump sum for a paid-up licence covering the remaining patent term. What actually flows depends on the size of the royalty base, the licensee's real sales volume, the strength and breadth of the claims, whether the licence is exclusive, and how easily the invention can be designed around.

Royalty stacking is a structural constraint: when a single product reads on patents held by many different owners, each licensor takes a slice, and the sum of all the slices limits what any one owner can demand without pricing the product out of the market.

In life sciences and materials science, milestone payments tied to trial completion or regulatory approval are often larger than early running royalties, because years pass before commercial sales exist to tax. Minimum annual royalties turn an exclusive licence into an income floor regardless of whether the licensee ever sells a unit, while a lump-sum paid-up licence trades away all of that future variability for cash today and ends the ongoing relationship entirely.

Costs and taxes

Obtaining and keeping the patent has unavoidable carrying costs: prosecution fees, per-country foreign filing costs, and maintenance fees on a statutory schedule. Enforcement is usually the larger expense — a demand letter can invite a declaratory judgment action or a petition for inter partes review at the Patent Trial and Appeal Board, and defending validity in either forum is expensive. Licensing agents and brokers take a commission for finding and negotiating deals, and contingency-fee litigation counsel typically take a large share of any infringement recovery.

For US tax purposes, licence royalties are generally ordinary income, reported on Form 1099-MISC and on Schedule E or as business income depending on whether the holder is regularly in the business of licensing. Section 1235 of the Internal Revenue Code offers a narrower path: a holder who transfers all substantial rights in a patent can treat the proceeds as long-term capital gain even when payments are contingent on the transferee's future sales — but the benefit turns entirely on whether the transfer genuinely conveys all substantial rights, not just a partial licence.

The 2017 tax law removed self-created patents from capital-asset treatment for most purposes, leaving Section 1235 as the main remaining route to capital-gain treatment for individual inventors. Foreign licensees withhold tax at source on royalty payments, reduced only where a valid treaty claim form has been filed in advance.

Liquidity and time commitment

Patents are sellable assets with brokers and occasional auction markets, but sale processes run for months and pricing is opaque and deal-specific rather than quoted anywhere. A signed licence with a creditworthy payer behaves more like a contract receivable and can sometimes be monetised or pledged as collateral, which is a somewhat more liquid position than the bare patent.

Getting to the first dollar is slow on its own: patent prosecution takes years before grant, and then identifying a licensee and negotiating terms takes more time on top of that. Ongoing effort after signing includes maintenance-fee docketing, reviewing royalty reports, exercising audit rights, monitoring the market for unlicensed use, and defending the patent against validity challenges when they arise. None of this pauses the clock — every year spent negotiating or litigating is a year of the fixed twenty-year term burned down.

How it goes wrong

The patent can be invalidated in an inter partes review or in litigation, which removes the foundation under every licence built on it simultaneously. A licensee can design around the claims during the course of the relationship — having learned the technology in the process — and then stop owing anything at all.

A loosely defined royalty base is a recurring failure point: a licensee can restructure sales, sell components separately, bundle products, or route transactions through an affiliate so that reported net sales shrink even as underlying commercial activity continues. An exclusive licensee can also simply shelve the technology to protect a competing product line, and without a minimum-royalty or diligence obligation in the contract the owner has no remedy for that inaction.

Administrative lapses matter as much as legal ones: missing a maintenance fee ends the patent and every royalty obligation tied to it. Enforcement costs can exceed the value of the royalty stream entirely, turning a patent that looks valuable on paper into one that is not worth defending. And external constraints — a FRAND licensing commitment, or a patent-exhaustion argument from a downstream buyer — can cap what can be charged far below what the owner originally assumed.